μ-opioid receptor knockout mice are insensitive to methamphetamine- induced behavioral sensitization

Journal of Neuroscience Research

Volumn 88, Issue 10, 2010, Pages 2294-2302

  Shen, Xine ^a,b   Purser, Chris ^a   Tien, Lu Tai ^a,c   Chiu, Chi Tso ^a   Paul, Ian A ^a   Baker, Rodney ^a   Loh, Horace H ^d   Ho, Ing K ^a,e   Ma, Tangeng ^a  

^a UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

^b SOOCHOW UNIVERSITY   (China)

^c FU JEN CATHOLIC UNIVERSITY   (Taiwan)

^d UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^e NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

Author keywords

Drug abuse; Locomotor activity; Stereotyped behaviors

Indexed keywords

AMPHETAMINE; METHAMPHETAMINE; MU OPIATE RECEPTOR; CENTRAL STIMULANT AGENT; DOPAMINE RECEPTOR BLOCKING AGENT; HALOPERIDOL;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG ABUSE; DRUG EFFECT; DRUG SENSITIZATION; KNOCKOUT MOUSE; LOCOMOTION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR INTRINSIC ACTIVITY; STEREOTYPY; AKATHISIA, DRUG-INDUCED; ANIMAL; BLOOD; C57BL MOUSE; DEFICIENCY; DOSE RESPONSE; DRUG EFFECTS; GENETICS; METABOLISM; MOTOR ACTIVITY;

AKATHISIA, DRUG-INDUCED; AMPHETAMINE; ANIMALS; CENTRAL NERVOUS SYSTEM STIMULANTS; DOPAMINE ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; HALOPERIDOL; MALE; METHAMPHETAMINE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MOTOR ACTIVITY; RECEPTORS, OPIOID, MU; STEREOTYPED BEHAVIOR;

EID: 77953633261     PISSN: 03604012     EISSN: 10974547     Source Type: Journal    
DOI: 10.1002/jnr.22386     Document Type: Article

References (32)

1. Bartlett E, Hallin A, Chapman B, Angrist B. 1997. Selective sensitization to the psychosis-inducing effects of cocaine: a possible marker for addiction relapse vulnerability? Neuropsychopharmacology 16:77-82.
2. Callaway CW, Kuczenski R, Segal DS. 1989. Reserpine enhances amphetamine stereotypies without increasing amphetamine-induced changes in striatal dialysate dopamine. Brain Res 505:83-90.
3. Chiu CT, Ma T, Ho IK. 2005. Attenuation of methamphetamine-induced behavioral sensitization in mice by systemic administration of naltrexone. Brain Res Bull 67:100-109.
4. Costall B, Naylor RJ, Olley JE. 1972. The substantia nigra and stereotyped behaviour. Eur J Pharmacol 18:95-106.
5. Devine DP, Leone P, Wise RA. 1993. Mesolimbic dopamine neurotransmission is increased by administration of mu-opioid receptor antagonists. Eur J Pharmacol 243:55-64.
6. Di Chiara G, Imperato A. 1988. Opposite effects of mu and kappa opiate agonists on dopamine release in the nucleus accumbens and in the dorsal caudate of freely moving rats. J Pharmacol Exp Ther 244:1067-1080. (Pubitemid 18090131)
7. Feigenbaum JJ, Howard SG. 1997. Effects of naloxone on amphetamine induced striatal dopamine release in vivo: a microdialysis study. Life Sci 60:1659-1668.
8. Feldman RS, Meyer JS, Quenzer LF. 1997. Principles of neuropsychopharmacology. Sunderland, MA: Sinauer Associates Inc. p 549-590.
9. Fenton JJ. 2002. Drug of abuse. In: Fenton JJ, editor. Toxicology: a case-oriented approach. Boca Raton, FL: CRC Press. p 359-402.
10. Hodler C, Paquet B, Gilbert F, Drolet G, Levesque D, Rouillard C. 2005.Role of endogenous enkephalin and dynorphin in amphetamine-induced behavioral sensitization. Society of Neuroscience 35th Annual Meeting, Washington, DC, abstract 1029.7
11. Hyman SE, Malenka RC, Nestler EJ. 2006. Neural mechanisms of addiction: the role of reward-related learning and memory. Annu Rev Neurosci 29:565-598.
12. Itzhak Y, Ali SF. 2002. Behavioral consequences of methamphetamine- induced neurotoxicity in mice: relevance to the psychopathology of methamphetamine addiction. Ann N Y Acad Sci 965:127-135. (Pubitemid 34721962)
13. Iversen SD, Kelly PH, Miller RJ, Seviour P. 1975. Proceedings: amphetamine and apomorphine responses in the rat after lesion of mesolimbic or striatal dopamine neurones. Br J Pharmacol 54:244P.
14. Johnson SW, North RA. 1992. Opioids excite dopamine neurons by hyperpolarization of local interneurons. J Neurosci 12:483-488.
15. Kelley AE, Lang CG, Gauthier AM. 1988. Induction of oral stereotypy following amphetamine microinjection into a discrete subregion of the striatum. Psychopharmacology 95:556-559.
16. Knapp RJ, Malatynska E, Collins N, Fang L, Wang JY, Hruby VJ, Roeske WR, Yamamura HI. 1995. Molecular biology and pharmacology of cloned opioid receptors. FASEB J 9:516-525.
17. Lan KC, Ma T, Lin-Shiau SY, Liu SH, Ho IK. 2008. Methamphetamine- elicited alterations of dopamine- and serotonin-metabolite levels within mu-opioid receptor knockout mice: a microdialysis study. J Biomed Sci 15:391-403.
18. Leite-Morris KA, Fukudome EY, Shoeb MH, Kaplan GB. 2004. GABAB receptor activation in the ventral tegmental area inhibits the acquisition and expression of opiate-induced motor sensitization. J Pharmacol Exp Ther 308:667-678.
19. Liste I, Munoz A, Guerra MJ, Labandeira-Garcia JL. 2000. Fenfluramine-induced Increase in preproenkephalin mRNA levels in the striatum: interaction between the serotonergic, glutamatergic, and dopaminergic systems. Synapse 35:182-191.
20. Loh HH, Liu HC, Cavalli A, Yang W, Chen YF, Wei LN. 1998. Mu opioid receptor knockout in mice: effects on ligand-induced analgesia and morphine lethality. Brain Res Mol Brain Res 54:321-326.
21. Mansour A, Fox CA, Akil H, Watson SJ. 1995. Opioid-receptor mRNA expression in the rat CNS: anatomical and functional implications. Trends Neurosci 18:22-29.
22. Matthews RT, German DC. 1984. Electrophysiological evidence for excitation of rat ventral tegmental area dopamine neurons by morphine. Neuroscience 11:617-625.
23. NTP-CERHR. 2005. Monograph on the potential human reproductive and developmental effects of amphetamines. Bethesda, MD: NIH Publication No. 05-4474.
24. Pereira FC, Lourenço ES, Borges F, Morgadinho T, Ribeiro CF, Macedo TR, Ali SF. 2006. Single or multiple injections of methamphetamine increased dopamine turnover but did not decrease tyrosine hydroxylase levels or cleave caspase-3 in caudate-putamen. Synapse 60:185-193.
25. Pijnenburg AJ, Honig WM, Van der Heyden JA, Van Rossum JM. 1976. Effects of chemical stimulation of the mesolimbic dopamine system upon locomotor activity. Eur J Pharmacol 35:45-58.
26. Robinson TE, Berridge KC. 2008. The incentive sensitization theory of addiction: some current issues. Philos Trans R Soc Lond B Biol Sci 363:3137-3146.
27. Schad CA, Justice JB Jr, Holtzman SG. 2002. Endogenous opioids in dopaminergic cell body regions modulate amphetamine-induced increases in extracellular dopamine levels in the terminal regions. J Pharmacol Exp Ther 300:932-938.
28. Sesack SR, Pickel VM. 1992. Dual ultrastructural localization of enkephalin and tyrosine hydroxylase immunoreactivity in the rat ventral tegmental area: multiple substrates for opiate-dopamine interactions. J Neurosci 12:1335-1350.
29. Standaert DG, Galanter JM. 2008. Pharmacology of dopaminergic neurotransmission. In: Gola DE, Tashjian AH Jr, Armstrong EJ, Amstrong AW, editors. Principles of pharmacology - the pathophysiologic basis of drug therapy,2nd ed. Philadelphia: Lippincott Williams and Wilkins. p 185-205.
30. Tien L-T, Ho IK, Loh HH, Ma T. 2007. Role of mu-opioid receptor in modulation of preproenkephalin mRNA expression and opioid and dopamine receptor binding in methamphetamine-sensitized mice. J Neurosci Res 85:673-680.
31. Ujike H, Akiyama K, Otsuki S., 1990. D-2 but not D-1 dopamine agonists produce augmented behavioral response in rats after subchronic treatment with methamphetamine or cocaine. Psychopharmacology 102:459-464. (Pubitemid 20379499)
32. Wang JQ, McGinty JF. 1995. Differential effects of D1 and D2 dopamine receptor antagonists on acute amphetamine- or methamphetamine-induced up-regulation of zif/268 mRNA expression in rat forebrain. J Neurochem 65:2706-2715.